(Total Views: 450)
Posted On: 08/14/2024 10:55:49 PM
Post# of 154646
Cancernetwork mention & 2022 excerpts:
"Results from the study showed a median PFS of 3.8 months (95% CI, 2.3-6.2) and a median OS of 6.6 months (95% CI, 4.9-not evaluable [NE]) across all patient cohorts. In patients treated with 525 mg or 700 mg leronlimab (n = 19), median PFS was 6.1 months (95% CI, 2.3-7.5) and the median OS was more than 12 months (95% CI, 5.5-12+)."
https://www.cancernetwork.com/view/fda-holds-...5-mss-mcrc
"Results from the study showed a median PFS of 3.8 months (95% CI, 2.3-6.2) and a median OS of 6.6 months (95% CI, 4.9-not evaluable [NE]) across all patient cohorts. In patients treated with 525 mg or 700 mg leronlimab (n = 19), median PFS was 6.1 months (95% CI, 2.3-7.5) and the median OS was more than 12 months (95% CI, 5.5-12+)."
https://www.cancernetwork.com/view/fda-holds-...5-mss-mcrc
(2)
(0)
